According to healthcare expert Eric Lefkofsky, leading the way into artificial intelligence as it relates to medicine, Tempus recently announced a years-long partnership with medical giant AstraZeneca. During this partnership, Eric Lefkofksy explains, both companies will work hand-in-hand to gain valuable data, find new target audiences and create therapeutics amongst the oncology markets.
Through harnessing the power of both a biopharma and a tech company, both groups aim to push the needle further on the way to discovering drugs more quickly to deliver them to those who are in need in addition to helping oncologists and healthcare professionals. The chief executive officer and founder of Tempus, Eric Lefkofsky, notes that AI has the incredible ability to push the limits of precision medicine in arenas that weren’t even fathomable a few years ago.
Through these integrations with artificial intelligence, patients will be able to live much longer and robust lives. Now, thanks to the success of Tempus through Eric Lefkofsky’s steady leadership, Tempus is exploring going public through an initial public offering according to those close to Tempus leaders. This could occur as soon as early 2022, though, admittedly, this is a rough timeline and plans could change over time. Tempus was valued in late 2020 at $8.1 billion after a $200 million financing round and a $250 million convertible debt move.
More on Eric Lefkofsky´s professional career https://www.crainsdetroit.com/detroit-homecoming/eric-lefkofsky-raises-200-million-new-startup-rick-french-helps-secure-music